PBAC's latest decision on Pregabalin: Deferred (2021). Considered for Treatment of neuropathic pain in adults. The submission also noted TGA registration for adjunctive therapy in adults with partial seizures, but the PBAC assessment focused on neuropathic pain.
PBAC outcome
Deferred
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
6
first 2005
Submissions
6
2005 → 2021
Eligible population
Adults with neuropathic pain requiring pregabalin at doses of 150–600 mg per day.
Therapy area
Pain
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
pregabalin capsules (currently PBS-listed)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Pricing data and financial implications are redacted in the PSD.
ICER (historical)
$15k/QALY across 2 submissions (2005–2011) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.